ERBB2 and breast cancer: In the most recent ongoing phase II trial (The DEBBRAH trial), one cohort of patients included both HER-2 + and HER-2 low breast cancer patients presenting with asymptomatic and untreated BM showed ORR- intracranial (IC) of 50%.